当前位置:首页 - 行情中心 - 东宝生物(300239) - 财务分析 - 利润表

东宝生物

(300239)

  

流通市值:26.60亿  总市值:30.63亿
流通股本:5.16亿   总股本:5.94亿

利润表

报告期2023-09-302023-06-302023-03-312022-12-31
公司类型通用通用通用通用
一、营业总收入734,671,103.09520,698,643.54261,319,537.08943,396,998.69
营业收入734,671,103.09520,698,643.54261,319,537.08943,396,998.69
二、营业总成本618,064,708.07439,435,410.63220,984,145.75819,583,116.98
营业成本538,072,682.27384,261,635.11194,396,384.41709,962,063.8
税金及附加9,649,008.087,002,352.693,317,255.7812,523,207.49
销售费用13,832,950.669,319,435.694,778,552.4217,837,199.89
管理费用37,130,253.8825,889,331.0212,342,950.2151,233,607.88
研发费用19,739,946.7512,948,212.645,950,698.7425,831,595.08
财务费用-360,133.5714,443.48198,304.192,195,442.84
其中:利息费用4,121,449.462,857,9101,601,6557,627,995.83
其中:利息收入4,409,565.222,775,032.071,461,162.54,840,922.31
加:投资收益-3,647,909.07-2,385,456.84-762,999.34-1,910,778.68
资产处置收益28,498.0528,498.051,531.63136,576.3
资产减值损失(新)19,226.86177,310.5176,072.03-1,056,717.92
信用减值损失(新)-510,785.4644,132.27175,496.4-518,691.57
其他收益6,437,432.482,980,385.641,287,359.6710,050,262.65
营业利润平衡项目0000
四、营业利润118,932,857.8882,108,102.5341,212,851.72130,514,532.49
加:营业外收入495,058.3136,960.59,982.361,687,859.44
减:营业外支出425,242.42227,936.48112,027.07555,338.56
利润总额平衡项目0000
五、利润总额119,002,673.7781,917,126.5541,110,807.01131,647,053.37
减:所得税费用17,070,063.9811,324,317.216,423,579.8216,211,098.85
六、净利润101,932,609.7970,592,809.3434,687,227.19115,435,954.52
持续经营净利润101,932,609.7970,592,809.3434,687,227.19115,435,954.52
归属于母公司股东的净利润95,261,690.0565,004,093.4331,137,429.27109,437,321.14
少数股东损益6,670,919.745,588,715.913,549,797.925,998,633.38
(一)基本每股收益0.160.110.050.18
(二)稀释每股收益0.160.110.050.18
九、综合收益总额101,932,609.7970,592,809.3434,687,227.19115,435,954.52
归属于母公司股东的综合收益总额95,261,690.0565,004,093.4331,137,429.27109,437,321.14
归属于少数股东的综合收益总额6,670,919.745,588,715.913,549,797.925,998,633.38
公告日期2023-10-302023-08-292023-04-262023-03-22
审计意见(境内)标准无保留意见
TOP↑